{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T22:40:26Z","timestamp":1707950426844},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1007\/s11940-001-0047-0","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T06:21:50Z","timestamp":1181197310000},"page":"127-131","source":"Crossref","is-referenced-by-count":8,"title":["Lambert-eaton myasthenic syndrome"],"prefix":"10.1007","volume":"3","author":[{"given":"John","family":"Newsom-Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"47_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/oso\/9780195129700.003.0009","volume-title":"Myasthenia Gravis and Myasthenic Disorders","author":"J Newsom-Davis","year":"1999","unstructured":"Newsom-Davis J, Lang B: The Lambert-Eaton myasthenic syndrome. In Myasthenia Gravis and Myasthenic Disorders. Edited by Engel AG. New York and Oxford: Oxford University Press; 1999:205\u2013228. Reviews the pathophysiology, pathogenesis, and management of LEMS."},{"key":"47_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O\u2019Neill","year":"1988","unstructured":"O\u2019Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 1988, 111:577\u2013596.","journal-title":"Brain"},{"key":"47_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","volume":"353","author":"P Maddison","year":"1999","unstructured":"Maddison P, Newsom-Davis J, Mills KR, Souhami RL: Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999, 353:117\u2013118.","journal-title":"Lancet"},{"key":"47_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1749-6632.1971.tb30750.x","volume":"183","author":"EH Lambert","year":"1971","unstructured":"Lambert EH, Elmqvist D: Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci 1971, 183:183\u2013199.","journal-title":"Ann N Y Acad Sci"},{"key":"47_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/ana.410420204","volume":"42","author":"SA Waterman","year":"1997","unstructured":"Waterman SA, Lang B, Newsom-Davis J: Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol 1997, 42:147\u2013156. Demonstrates that LEMS IgG impairs cholinergic and adrenergic function at autonomic synapses.","journal-title":"Ann Neurol"},{"key":"47_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ana.410430520","volume":"43","author":"H Houzen","year":"1998","unstructured":"Houzen H, Hattori Y, Kanno M, et al.: Functional evaluation of inhibition of autonomic transmitter release by autoantibody from Lambert-Eaton myasthenic syndrome. Ann Neurol 1998, 43:677\u2013680.","journal-title":"Ann Neurol"},{"key":"47_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/jnnp.65.2.213","volume":"65","author":"P Maddison","year":"1998","unstructured":"Maddison P, Newsom-Davis J, Mills KR: Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1998, 65:213\u2013217.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"47_CR8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/(SICI)1097-4598(199607)19:7<903::AID-MUS15>3.0.CO;2-J","volume":"19","author":"SJ Oh","year":"1996","unstructured":"Oh SJ, Kim DE, Kuruoglu R, et al.: Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1996, 19:903\u2013906.","journal-title":"Muscle Nerve"},{"key":"47_CR9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","volume":"58","author":"M Motomura","year":"1995","unstructured":"Motomura M, Johnston I, Lang B, et al.: An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995, 58:85\u201387.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"47_CR10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, et al.: Calciumchannel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995, 332:1467\u20131474.","journal-title":"N Engl J Med"},{"key":"47_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1749-6632.1998.tb11023.x","volume":"841","author":"J Newsom-Davis","year":"1998","unstructured":"Newsom-Davis J: A treatment algorithm for Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998, 841:817\u2013822.","journal-title":"Ann N Y Acad Sci"},{"key":"47_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1749-6632.1998.tb11025.x","volume":"841","author":"SJ Oh","year":"1998","unstructured":"Oh SJ, Kim DS, Kwon KH, et al.: Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1998, 841:827\u2013831.","journal-title":"Ann N Y Acad Sci"},{"key":"47_CR13","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1146::AID-MUS9>3.0.CO;2-8","volume":"20","author":"SJ Oh","year":"1997","unstructured":"Oh SJ, Kim DS, Head TC, Claussen GC: Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1997, 20:1146\u20131152.","journal-title":"Muscle Nerve"},{"key":"47_CR14","doi-asserted-by":"publisher","first-page":"R295","DOI":"10.1007\/BF02346385","volume":"431","author":"J Molgo","year":"1996","unstructured":"Molgo J, Guglielmi JM: 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Pflugers Arch 1996, 431:R295-R296.","journal-title":"Pflugers Arch"},{"key":"47_CR15","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","volume":"321","author":"KM McEvoy","year":"1989","unstructured":"McEvoy KM, Windebank AJ, Daube JR, Low PA: 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989, 321:1567\u20131571.","journal-title":"N Engl J Med"},{"key":"47_CR16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"SandersDB, Massey JM, Sanders LL, Edwards LJ: A randomized trial of 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000, 54:603\u2013607. Shows that 3,4-diaminopyridine is a safe and effective treatment in LEMS.","journal-title":"Neurology"},{"key":"47_CR17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","volume":"40","author":"CH Chalk","year":"1990","unstructured":"Chalk CH, Murray NM, Newsom-Davis J, et al.: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990, 40:1552\u20131556.","journal-title":"Neurology"},{"key":"47_CR18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","volume":"34","author":"J Newsom-Davis","year":"1984","unstructured":"Newsom-Davis J, Murray NM: Plasma exchange and immunosuppressive drug therapy in the Lambert-Eaton myasthenic syndrome. Neurology 1984, 34:480\u2013485.","journal-title":"Neurology"},{"key":"47_CR19","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"PG Bain","year":"1996","unstructured":"BainPG, Motomura M, Newsom-Davis J, et al.: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996, 47:678\u2013683. Double-blind crossover study showing that a course of intravenous immunoglobulin treatment significantly improves muscle strength and lowers serum calcium channel antibodies for a 6 to 8 week period.","journal-title":"Neurology"},{"key":"47_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<614::AID-MUS13>3.0.CO;2-W","volume":"20","author":"MM Rich","year":"1997","unstructured":"Rich MM, Teener JW, Bird SJ: Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 1997, 20:614\u2013615.","journal-title":"Muscle Nerve"},{"key":"47_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5","volume":"20","author":"S Muchnik","year":"1997","unstructured":"Muchnik S, Losavio AS, Vidal A, et al.: Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 1997, 20:674\u2013678.","journal-title":"Muscle Nerve"},{"key":"47_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3109\/15563659509017992","volume":"33","author":"CE Boerma","year":"1995","unstructured":"Boerma CE, Rommes JH, van Leeuwen RB, Bakker J: Cardiac arrest following an iatrogenic 3,4-Diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J Toxicol Clin Toxicol 1995, 33:249\u2013251.","journal-title":"J Toxicol Clin Toxicol"},{"key":"47_CR23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2165\/00002018-199309040-00003","volume":"9","author":"SA Misbah","year":"1993","unstructured":"Misbah SA, Chapel HM: Adverse effects of intravenous immunoglobulin. Drug Safety 1993, 9:254\u2013262.","journal-title":"Drug Safety"},{"key":"47_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/mus.880121010","volume":"12","author":"SH Oh","year":"1989","unstructured":"Oh SH: SFEMG improvements in the cancer-associated Lambert-Eaton myasthenic syndrome. Muscle Nerve 1989, 12:844\u2013848.","journal-title":"Muscle Nerve"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-001-0047-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0047-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-001-0047-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T22:22:31Z","timestamp":1707949351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-001-0047-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["47"],"URL":"https:\/\/doi.org\/10.1007\/s11940-001-0047-0","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}